With over 15 years of experience in contract development services, we we have consistently delivered innovative scientific solutions for biopharmaceutical development. Our core competencies revolve around the establishment of high titer stable cell lines within mammalian expression systems, the implementation of robust process development, and comprehensive analytical development tailored for pre-clinical and clinical sample monitoring A glance at our versatile service portfolio:
- Cell line development using both, our potent and cost-attractive CHOnamite® (CHO-K1; CHO-DG44, CHO-GS-KO) and the flexible human GlycoExpress® (GEX®) platform technology for complex glycoproteins Note: Productivity of our CHOnamite® platform ( between 8-12 g/L for IgG1 based molecules), including our transposase system ranks among the highest titers achieved in the global biotech scene New: CHOFlow® technology for ADCC enhanced afucosylated mAb formats
- Customized feasibility studies to select the best suitable host cell line meeting the specific requirements for each individual complex recombinant protein
- Integrated robust USP/DSP development as well as analytical development to accelerate timelines
- Extensive protein characterization (e.g., PTMs; N-Glycans; O-Glycans) ensured by our in-depth expertise in mass spectrometry
- Bioassay development (e.g., ADCC, CDC; ELISA, FACS)
- Clinical bioanalysis (e.g., PK, ADA, nAb) from proteins to oligonucleotides under GCLP regulations
